AbbVie Inc (ABBV)vsOncology Institute Inc (TOI)
ABBV
AbbVie Inc
$206.60
-2.23%
HEALTHCARE · Cap: $360.63B
TOI
Oncology Institute Inc
$4.05
+4.92%
HEALTHCARE · Cap: $366.69M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 12066% more annual revenue ($61.16B vs $502.73M). ABBV leads profitability with a 6.9% profit margin vs -12.1%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
TOI
Hold45
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-26.3%
Fair Value
$163.59
Current Price
$206.60
$43.01 premium
Margin of Safety
+80.1%
Fair Value
$13.17
Current Price
$4.05
$9.12 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Revenue surging 41.6% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -652.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : TOI
The strongest argument for TOI centers on Revenue Growth, Debt/Equity. Revenue growth of 41.6% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : TOI
The primary concerns for TOI are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
ABBV profiles as a value stock while TOI is a hypergrowth play — different risk/reward profiles.
ABBV carries more volatility with a beta of 0.36 — expect wider price swings.
TOI is growing revenue faster at 41.6% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 45/100). TOI offers better value entry with a 80.1% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Oncology Institute Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Oncology Institute Inc (ticker: TOI) is a pioneering healthcare organization dedicated to transforming cancer care through its extensive network of specialized clinics and innovative treatment modalities. The company prioritizes enhanced patient outcomes by leveraging state-of-the-art technologies and customized treatment plans, while also participating in clinical trials and collaborations with leading research institutions. As the need for advanced cancer therapies continues to grow, TOI is strategically positioned to leverage its robust pipeline and deep-seated oncology expertise, reinforcing its status as a key player in the evolving healthcare sector.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?